DaVita Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 5, 2026 at 3:30 PM GMT+3 3 min read

DaVita Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance and Operational Context

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Volume growth acceleration was primarily driven by sustained improvements in patient mortality, which management attributes to successful clinical execution and better management of phosphate levels.
The transition of phosphate binders into the Medicare dialysis bundle has reduced reliance on less effective over-the-counter options by more than 50%, expanding access to clinically preferred therapies.
Revenue per treatment declined sequentially due to lower commercial mix following the expiration of ACA subsidies and lower sequential revenue contribution from phosphate binders.
Management is pivoting toward middle molecule clearance technology, specifically expanded hemodialysis (HD), which offers mortality benefits without requiring significant new capital investment in machines.
The recent FDA approval of new expanded HD dialyzers from NIPRO is expected to materially improve market supply and economics for advanced dialysis treatments.
U.S. dialysis operating income remained relatively flat year-over-year as treatment growth was offset by elevated cost per treatment and a 10% increase in G&A spending.
Capacity utilization currently sits in the high 50s, providing significant room for volume expansion compared to pre-pandemic peaks of approximately 65%.

Strategic Outlook and Guidance Assumptions

Management reconfirmed full-year 2026 adjusted operating income guidance of $2.2 billion, assuming a sequential increase of $50 million to $100 million from Q3 to Q4 driven by IKC timing.
Total treatment growth for 2026 is now expected at the top end of the 25 to 50 basis point range, supported by clinical outcomes that extend patient life.
Full-year revenue per treatment (RPT) growth is projected at 1% to 2%, implying slightly negative year-over-year growth in the second half due to declining commercial mix and lower binder revenue.
The company expects to return to treatment volume growth of at least 2% by 2029, underpinned by the broad deployment of middle molecule clearance therapies.
The financial impact of the 2027 ESRD proposed rule remains uncertain, as the current proposal suggests a rate increase that tracks below industry cost trends.

Structural Changes and Risk Factors

The $200 million minority investment in Elara Caring closed in July, intended to integrate dialysis-tailored home health services into the patient care model.
CMS has reduced its estimate for phosphate binder spend by nearly $500 million since the initial transition, highlighting the policy's impact on government spending.
Commercial mix headwinds are expected to result in a $40 million impact in 2026 and a $70 million impact in 2027 due to lower exchange plan effectuation rates.
Management noted that while mortality improved, volume was slightly tempered by fewer patient admits from closed competitor clinics and higher-than-expected missed treatments.

Q&A Session Highlights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Economic impact and timing of expanded HD deployment

Management clarified that while deployment will begin in the coming quarters, the financial impact will be insignificant until the mortality benefits materialize, likely in 2028.
The transition is operationally simple as it involves switching dialyzers rather than replacing existing dialysis machines.

Sustainability of Integrated Kidney Care (IKC) growth

Growth is driven by both margin expansion and increasing the number of lives under management through new Medicare Advantage contracts.
Management views IKC as a maturing business with significant room for continued contribution to enterprise operating income.

Capital allocation and share repurchase strategy

The company maintains its leverage target of 3.0x to 3.5x EBITDA and remains committed to its buyback strategy despite the recent stock price appreciation.
Repurchases were front-loaded in the first half of the year, with recent activity moderated by the $200 million cash outlay for the Elara Caring investment.